Cti Biopharma Corp Stock Current Ratio
CTi Biopharma Corp fundamentals help investors to digest information that contributes to CTi Biopharma's financial success or failures. It also enables traders to predict the movement of CTi Stock. The fundamental analysis module provides a way to measure CTi Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CTi Biopharma stock.
CTi |
CTi Biopharma Corp Company Current Ratio Analysis
CTi Biopharma's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current CTi Biopharma Current Ratio | 3.26 X |
Most of CTi Biopharma's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CTi Biopharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
CompetitionIn accordance with the recently published financial statements, CTi Biopharma Corp has a Current Ratio of 3.26 times. This is 12.03% higher than that of the Biotechnology sector and 53.43% lower than that of the Health Care industry. The current ratio for all United States stocks is 50.93% lower than that of the firm.
CTi Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CTi Biopharma's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CTi Biopharma could also be used in its relative valuation, which is a method of valuing CTi Biopharma by comparing valuation metrics of similar companies.CTi Biopharma is currently under evaluation in current ratio category among its peers.
CTi Fundamentals
| Return On Equity | -10.19 | |||
| Return On Asset | -0.29 | |||
| Profit Margin | (0.91) % | |||
| Operating Margin | (0.74) % | |||
| Current Valuation | 1.26 B | |||
| Shares Outstanding | 131.88 M | |||
| Shares Owned By Insiders | 5.49 % | |||
| Shares Owned By Institutions | 83.28 % | |||
| Number Of Shares Shorted | 11.27 M | |||
| Price To Earning | (1.68) X | |||
| Price To Book | 112.63 X | |||
| Price To Sales | 22.01 X | |||
| Revenue | 53.95 M | |||
| Gross Profit | 50.43 M | |||
| EBITDA | (79.85 M) | |||
| Net Income | (92.99 M) | |||
| Cash And Equivalents | 81.64 M | |||
| Cash Per Share | 0.64 X | |||
| Total Debt | 49.96 M | |||
| Current Ratio | 3.26 X | |||
| Book Value Per Share | (0.19) X | |||
| Cash Flow From Operations | (81.19 M) | |||
| Short Ratio | 1.08 X | |||
| Earnings Per Share | (0.54) X | |||
| Target Price | 10.05 | |||
| Number Of Employees | 127 | |||
| Beta | 0.83 | |||
| Market Capitalization | 1.2 B | |||
| Total Asset | 125.92 M | |||
| Retained Earnings | (2.52 B) | |||
| Working Capital | 18.26 M | |||
| Current Asset | 134.97 M | |||
| Current Liabilities | 72.41 M | |||
| Z Score | -15.1 | |||
| Net Asset | 125.92 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in CTi Stock
If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |